| Botulinum Toxin for Palliative Treatment of Epiphora in Patients with Nasolacrimal Duct Obstruction. |
|
Jung Ho Lee, Dae Yune Kim, Kwang Soo Kim |
1Department of Ophthalmology, Dongguk University Gyeongju Hospital, Gyeonbuk, Korea.
2Department of Ophthalmology, Haenam Hospital, Jeonnam, Korea. daeyun115@hanmail.net |
| 비루관폐쇄 환자에서 보툴리눔 A 독소를 이용한 보존적 치료 |
|
이중호1,김대윤2,김광수1 |
|
Department of Ophthalmology, Dongguk University Gyeongju Hospital1, Gyeonbuk, Korea Department of Ophthalmology, Haenam Hospital2, Jeonnam, Korea |
|
Correspondence:
Dae Yune Kim, M.D. |
|
|
| Abstract |
PURPOSE
To describe the use of botulinum toxin injection of the lacrimal gland for palliative treatment of epiphora secondary to nasolacrimal duct obstruction. METHODS: A prospective non-comparative interventional case series study was designed to include 13 patients with nasolacrimal duct obstruction. Under topical anesthesia botulinum toxin A (1-4unit) was injected into the palpebral lobe of the lacrimal gland via a transconjunctival approach. Patients underwent a Schirmer test and a subjective evaluation of their epiphora symptoms was performed at 0 (baseline), 1, 4 and 12 weeks after injection. RESULTS: Subjective epiphora scores improved in 10 out of the 13 patients (76.9%). Schirmer test results showed objective reduction in tearing from baseline but did not strongly correlate with the subjective epiphora scores. Transient ptosis were experienced by two patients. CONCLUSIONS: Botulinum A toxin injection for palliative treatment of epiphora secondary to nasolacrimal duct obstruction is a simple, effective and safe treatment. |
| Key Words:
Botulinum A toxin;Lacrimal gland;Nasolacrimal duct obstruction |
|
PDF Links
Full text via DOI
Download Citation
